ERBB2 and breast cancer: Despite advances in treatments like chemotherapy, endocrine therapy, and human epidermal growth factor receptor-2 (HER2)-targeted therapy, the chance of relapse and BC metastasis remains a great challenge (Zhu and Yu, 2022).